Cytogenetic heterogeneity and their serial dynamic changes during acquisition of cytogenetic aberrations in cultured mesenchymal stem cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 777, Issue , 2015, Pages 60-68

  Kim, Jung Ah ^a   Im, Kyong Ok ^a   Park, Si Nae ^a   Kwon, Ji Seok ^a   Kim, Seon Young ^a   Oh, Keunhee ^a   Lee, Dong Sup ^a   Kim, Min Kyung ^b   Kim, Seong Who ^b   Jang, Mi ^c   Lee, Gene ^c   Oh, Yeon Mok ^b   Lee, Sang Do ^b   Lee, Dong Soon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Cytogenetic aberration; Fluorescence hybridization; Heterogeneity; Mesenchymal stem cells; Telomere

Indexed keywords

ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; G BANDING ANALYSIS; GENETIC HETEROGENEITY; GENETIC PROCEDURES; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TELOMERE HOMEOSTASIS; UMBILICAL CORD; ANIMAL; BACTERIAL ARTIFICIAL CHROMOSOME; CELL CLONE; CHROMOSOME BANDING PATTERN; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOLOGY; DRUG EFFECTS; GENETICS; INTERPHASE; KARYOTYPING; MESENCHYMAL STROMA CELL; METAPHASE; NONOBESE DIABETIC MOUSE; TELOMERE; TUMOR CELL LINE;

ADIPOSE TISSUE; ANIMALS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLONE CELLS; CORD BLOOD STEM CELL TRANSPLANTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KARYOTYPING; MESENCHYMAL STROMAL CELLS; METAPHASE; MICE; MICE, INBRED NOD; TELOMERE;

EID: 84929329783     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2015.04.003     Document Type: Article

References (23)

1. Maitra A., Arking D.E., Shivapurkar N., Ikeda M., Stastny V., Kassauei K., Sui G., Cutler D.J., Liu Y., Brimble S.N., Noaksson K., Hyllner J., Schulz T.C., Zeng X., Freed W.J., Crook J., Abraham S., Colman A., Sartipy P., Matsui S., Carpenter M., Gazdar A.F., Rao M., Chakravarti A. Genomic alterations in cultured human embryonic stem cells. Nat. Genet. 2005, 37:1099-1103.
2. Guidelines for the Clinical Translation of Stem Cells 2008, 1-19. International Society for Stem Cell Research.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 610.1016/j.cell.2011.1002.1013.
4. Hovatta O., Jaconi M., Tohonen V., Bena F., Gimelli S., Bosman A., Holm F., Wyder S., Zdobnov E.M., Irion O., Andrews P.W., Antonarakis S.E., Zucchelli M., Kere J., Feki A. A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes. PLoS ONE 2010, 5:e10263.
5. Rubio D., Garcia-Castro J., Martin M.C., de la Fuente R., Cigudosa J.C., Lloyd A.C., Bernad A. Spontaneous human adult stem cell transformation. Cancer Res. 2005, 65:3035-3039.
6. Rosland G.V., Svendsen A., Torsvik A., Sobala E., McCormack E., Immervoll H., Mysliwietz J., Tonn J.C., Goldbrunner R., Lonning P.E., Bjerkvig R., Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009, 69:5331-5339.
7. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E., Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010, 7:521-531.
8. Kim S.Y., Im K., Park S.N., Kwon J., Kim J.A., Choi Q., Hwang S.M., Han S.H., Kwon S., Oh I.H., Lee D.S. Asymmetric aneuploidy in mesenchymal stromal cells detected by in situ karyotyping and fluorescence in situ hybridization: suggestions for reference values for stem cells. Stem Cells Dev. 2014, 8:8.
9. Lee J.K., Lee M.K., Jin H.J., Kim D.S., Yang Y.S., Oh W., Yang S.E., Park T.S., Lee S.Y., Kim B.S., Jeun S.S. Efficient intracytoplasmic labeling of human umbilical cord blood mesenchymal stromal cells with ferumoxides. Cell Transplant. 2007, 16:849-857.
10. Hwang S.M., See C.-J., Choi J., Kim S.Y., Choi Q., Kim J.A., Kwon J., Park S.N., Im K., Oh I.-H. The application of an in situ karyotyping technique for mesenchymal stromal cells: a validation and comparison study with classical G-banding. Exp. Mol. Med. 2013, 45:e68.
11. The AGT Cytogenics Laboratory Manual 1997, Lippincott-Raven Publishers, Philadelphia. 3rd ed.
12. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., Reeder T.L., Li C.Y., Cross N.C., Cools J., Gilliland D.G., Dewald G.W., Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
13. Perner S., Bruderlein S., Hasel C., Waibel I., Holdenried A., Ciloglu N., Chopurian H., Nielsen K.V., Plesch A., Hogel J., Moller P. Quantifying telomere lengths of human individual chromosome arms by centromere-calibrated fluorescence in situ hybridization and digital imaging. Am. J. Pathol. 2003, 163:1751-1756.
14. Narath R., Lorch T., Greulich-Bode K.M., Boukamp P., Ambros P.F. Automatic telomere length measurements in interphase nuclei by IQ-FISH. Cytom. A. 2005, 68:113-120.
15. Nordgren A., Heyman M., Sahlen S., Schoumans J., Soderhall S., Nordenskjold M., Blennow E. Spectral karyotyping and interphase FISH reveal abnormalities not detected by conventional G-banding. Implications for treatment stratification of childhood acute lymphoblastic leukaemia: detailed analysis of 70 cases. Eur. J. Haematol. 2002, 68:31-41.
16. Woo H.Y., Kim D.W., Park H., Seong K.W., Koo H.H., Kim S.H. Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia. J. Korean Med. Sci. 2005, 20:36-41.
17. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 2012, 198:281-293.
18. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
19. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., Escaramis G., Jares P., Bea S., Gonzalez-Diaz M., Bassaganyas L., Baumann T., Juan M., Lopez-Guerra M., Colomer D., Tubio J.M., Lopez C., Navarro A., Tornador C., Aymerich M., Rozman M., Hernandez J.M., Puente D.A., Freije J.M., Velasco G., Gutierrez-Fernandez A., Costa D., Carrio A., Guijarro S., Enjuanes A., Hernandez L., Yague J., Nicolas P., Romeo-Casabona C.M., Himmelbauer H., Castillo E., Dohm J.C., de Sanjose S., Piris M.A., de Alava E., San Miguel J., Royo R., Gelpi J.L., Torrents D., Orozco M., Pisano D.G., Valencia A., Guigo R., Bayes M., Heath S., Gut M., Klatt P., Marshall J., Raine K., Stebbings L.A., Futreal P.A., Stratton M.R., Campbell P.J., Gut I., Lopez-Guillermo A., Estivill X., Montserrat E., Lopez-Otin C., Campo E. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105. 110.1038/nature10113.
20. Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., van De Walle I., Cathelin S., Trimarchi T., Araldi E., Liu C., Ibrahim S., Beran M., Zavadil J., Efstratiadis A., Taghon T., Michor F., Levine R.L., Aifantis I. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473:230-233. 210.1038/nature09999.
21. Miura M., Miura Y., Padilla-Nash H.M., Molinolo A.A., Fu B., Patel V., Seo B.M., Sonoyama W., Zheng J.J., Baker C.C., Chen W., Ried T., Shi S. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103. Epub 2005 Nov 1010.
22. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs) 2008, 1-39. FDA.
23. Reflection Paper on Stem Cell-based Medicinal Products 2011, 1-14. European Medicines Agency.